Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora Musuamba Tshinanu

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Briefings in Bioinformatics|June 6, 2018
In silico clinical trials: concepts and early adoptionsFrancesco Pappalardo, Giulia Russo, Flora Musuamba Tshinanu, et al.
Methods (San Diego, Calif.)|January 29, 2020
In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical productsMarco Viceconti, Francesco Pappalardo, Blanca Rodriguez, et al.
Clinical Pharmacology and Therapeutics|January 3, 2025
Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMAPolly Paul, Pieter J Colin, Flora Musuamba Tshinanu, et al.
Clinical Pharmacology and Therapeutics|June 4, 2025
Reply to: "Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis"Polly Paul, Pieter J Colin, Flora Musuamba Tshinanu, et al.
Clinical Biochemistry|December 20, 2014
Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patientsMinh Thuan Nguyen Thi, Michel Mourad, Arnaud Capron, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2023
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspectiveEfthymios Manolis, Alfredo García-Arieta, Anders Lindahl, et al.
Clinical Pharmacology and Therapeutics|November 22, 2024
Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal HealthLuis Correia Pinheiro, Peter Arlett, Kit Roes, et al.
Gene Therapy|December 22, 2025
Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected casesPhilipp Berg, Charlotte Bakker, Moritz Sander, et al.
Clinical Pharmacology and Therapeutics|August 3, 2023
Model-Informed Drug Development: Steps Toward Harmonized GuidanceScott Marshall, Malidi Ahamadi, Jenny Chien, et al.
Molecular Pharmaceutics|July 1, 2024
Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary ReportXavier Pepin, Sumit Arora, Luiza Borges, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Briefings in Bioinformatics|June 6, 2018
In silico clinical trials: concepts and early adoptionsFrancesco Pappalardo, Giulia Russo, Flora Musuamba Tshinanu, et al.
Methods (San Diego, Calif.)|January 29, 2020
In silico trials: Verification, validation and uncertainty quantification of predictive models used in the regulatory evaluation of biomedical productsMarco Viceconti, Francesco Pappalardo, Blanca Rodriguez, et al.
Clinical Pharmacology and Therapeutics|January 3, 2025
Current Use of Physiologically Based Pharmacokinetic modeling in New Medicinal Product Approvals at EMAPolly Paul, Pieter J Colin, Flora Musuamba Tshinanu, et al.
Clinical Pharmacology and Therapeutics|June 4, 2025
Reply to: "Current Use of PBPK Modeling in New Medicinal Product Approvals at EMA: A Clinical Appraisal of Voclosporin in Lupus Nephritis"Polly Paul, Pieter J Colin, Flora Musuamba Tshinanu, et al.
Clinical Biochemistry|December 20, 2014
Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patientsMinh Thuan Nguyen Thi, Michel Mourad, Arnaud Capron, et al.
CPT: Pharmacometrics & Systems Pharmacology|January 11, 2023
Using mechanistic models to support development of complex generic drug products: European Medicines Agency perspectiveEfthymios Manolis, Alfredo García-Arieta, Anders Lindahl, et al.
Clinical Pharmacology and Therapeutics|November 22, 2024
Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal HealthLuis Correia Pinheiro, Peter Arlett, Kit Roes, et al.
Gene Therapy|December 22, 2025
Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected casesPhilipp Berg, Charlotte Bakker, Moritz Sander, et al.
Clinical Pharmacology and Therapeutics|August 3, 2023
Model-Informed Drug Development: Steps Toward Harmonized GuidanceScott Marshall, Malidi Ahamadi, Jenny Chien, et al.
Molecular Pharmaceutics|July 1, 2024
Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary ReportXavier Pepin, Sumit Arora, Luiza Borges, et al.
Pageof 2